FFlomics
Flomics is a Barcelona-based biotech company founded in 2018 that develops RNA-based liquid biopsy diagnostics, combining next-generation sequencing with machine learning to analyze circulating cell-free RNA (cfRNA) in blood. Its flagship product is a multicancer early-detection blood test targeting colorectal, lung, breast, prostate and pancreatic cancers, developed with clinical partners including Hospital Clínic Barcelona, Bern University Hospital and others. Founded by researchers/entrepreneurs from the Centre for Genomic Regulation (CRG) and Universitat Pompeu Fabra (UPF); has raised seed funding across multiple rounds (2022, 2024).
SectorsBiotechnology, Diagnostics, Liquid Biopsy, Genomics, Precision Medicine
Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing
Founders
A
André Guedes
COO & Co-founder
E
Esther Lizano
Chief Scientific Officer & Co-founder
J
João Curado
CEO & Co-founder
L
Luís Korrodi
Chief Business Officer & Co-founder
Global models 5
GGRAIL
United States · grail.com ↗
Develops a multi-cancer early detection blood test (Galleri) using cell-free nucleic acid sequencing and machine learning, the closest large-scale analog to Flomics' cfRNA multicancer screening approach.
$2.0B+Comparable
FFreenome
United States · www.freenome.com ↗
Uses blood-based multiomics (including cell-free RNA and proteins) plus machine learning for early cancer detection, directly mirroring Flomics' cfRNA plus ML diagnostic model.
$1.7BComparable
GGuardant Health
United States · guardanthealth.com ↗
Liquid biopsy company using blood-based genomic analysis for cancer detection and monitoring, same core NGS-based liquid biopsy category as Flomics.
$550M (pre-IPO VC)Comparable
T
Thrive Earlier Detection
United States
Developed a multi-cancer blood test (CancerSEEK) combining genomic and protein biomarkers, acquired by Exact Sciences for $2.15B, a close model match to Flomics' multicancer blood test.
$257MComparable
DDELFI Diagnostics
United States · delfidiagnostics.com ↗
Uses cell-free DNA fragmentation patterns and machine learning from a simple blood draw for early cancer detection, closely paralleling Flomics' cfRNA fragmentomics-plus-ML approach.
$300MComparable
In the same niche 48 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 6
Open as list →
AArcano Partners
www.arcanopartners.com
CCapital Cell
capitalcell.com
D
Decelera Ventures
decelera.co
H
Histemi Inversiones
I
Instituto Oncológico Doctor Rosell (IOR)
IInstituto Oncológico Dr. Rosell (IOR)
Funding rounds 3
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-07-12 | Seed (estimated) | €799K |
Lead not disclosed
+1 more
|
| 2024-03-06 | Seed | €1.1M |
Lead not disclosed
+3 more
|
| 2022-03-31 | Seed | €1M |
Lead not disclosed
+1 more
|
News
No coverage on record yet.